Keywords
Infantile hemangioma
Therapeutic efficacy
Safety
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the efficacy and safety of propranolol compared to other available therapeutic approaches, focusing on short- and long-term clinical outcomes. Methods: Integrative literature review in the PubMed Central (PMC) database, using the search strategy: ((Infantile hemangiomas) OR (IHs)) AND (Propranolol) from 2019 to 2024. After the initial search, 397 studies were identified and submitted to selection criteria. After applying inclusion and exclusion criteria, 13 articles were selected to compose this study. Results: Propranolol has been shown to be highly effective in reducing the size and proliferation of hemangiomas, with minimal adverse effects, when compared to other therapies, such as corticosteroids or surgical treatment. Early administration and strict monitoring are essential for therapeutic success. Regarding safety, adverse effects were, in most cases, mild and manageable, although pre- and post-treatment cardiac care is recommended. Final considerations: Propranolol is a safe and efficient option in the treatment of infantile hemangiomas. However, it is recommended that future studies explore optimized dosages and possible therapeutic combinations for refractory cases.
References
ABU-RMAILEH M, et al. Infantile Hemangioma Treated with Propranolol Readmission Trends, Complications of Therapy, and Cost: A PHIS Database Study. International Journal of Pediatrics, 2022; 22: 4423558.
ASHRAF R, et al. Comparing the Effectiveness of Propanolol versus Atenolol in Inducing Clinical Clearence in the Treatment of Infantile Haemangioma: A Randomised Controlled Trial. Indian Journal of Dermatology, 2023; 69: 148-155.
FEI Q, et al. Treatments for infantile Hemangioma: A systematic review and network meta-analysis. EClinicalMedicine 2020; 26: 100506.
GALQZKA P, et al. Treatment of haemangiomas using propranolol in paediatric patients: a retrospective cohort study. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020; 37(4): 603-607.
GUO L, et al. Addittive value of single intralesional bleomycin injection to propanolol in the management of proliferative infantile hemangioma. Asian Journal of Surgery, 2023; 47: 154-157.
GUPTA R. Propranolol for Vascular Anomalies: Efficacy and Complications in Pediatric Patients. Journal of Indian Association of Pediatric Surgeons, 2023; 28 (3): e10.4103.
HUANG CY, et al. Regimen for accelerated propranolol initial dosing (RAPID). Pediatr Dermatol, 2024;41(4):621‐627.
JUNG EL. Update on infantile hemangioma. Clinical and Experimental Pediatrics, 2021; 64(11): 559 - 572.
KIM JHS, LAM MJ. Paediatrics: how to manage infantile haemangioma. Drugs in Context, 2021; 10: 2020-12-6.
KWAK JH, et al. Cardiac evaluation before and after oral propranolol treatment for infantile hemangiomas. Journal of Clinical Medicine, 2024; 13:e3332.
LIU C, et al. Effect of combined low-dose oral prednisone with beta-adrenergic receptor antagonists for refractory infantile hemangiomas: retrospective cohort study in 76 patients. Ann Transl Med, 2019; 7(23):750.
MACCA L, et al. Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?. Frontiers in Pharmacology, 2022; 13: 1-8.
PANDEY A, et al. Evaluation of Effect of Propranolol on Serum Vascular Endothelial Growth Factor and Tissue Inhibitor of Metalloproteinase-2 Levels in Infantile Hemangioma. J Indian Assoc Pediatr Surg, 2020; 25(2): e96-102.
PUTTERMAN E, et al. “Evaluation of a modified outpatient model for using propranolol to treat infantile hemangiomas.” Pediatric dermatology, 2019; vol. 36,4: e471-476.
TAN JWH, et al. R(+) Propanolol decreases lipid accumalation in hemangioma-derived stem cells. BioRxiv: The preprint server for biology, 2024.
TAN X, et al. Propranolol in the Treatment of Infantile Hemangiomas. Clinical, Cosmetic and Investigational Dermatology, 2021; 14: 1155-1163.
WU C, et al. Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol. Medicine, 2019; 98:6 (e14346).
WU ZB, et al. Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis. Translational Pediatrics, 2021;10(7): e10.21037.
YANG H, et al. Efficacy and adverse efects of oral propranolol in infantile hemangioma: a meta‐analysis of comparative studies. World Journal of Pediatrics, 2019; 15(6): 546-558.
ZHU H, et al. Efficacy of timolol in the treatment of facial hemangioma and its effect on the proliferation and apoptosis of hemangioma stem cells. Cell Mol Biol (Noisy-le-grand), 2023; 69(10):115-120.